MXPA04004745A - Agonista de receptor de dopamina-d2 parcial y actividad inhibidora de serotonina y/o noradrenalina. - Google Patents

Agonista de receptor de dopamina-d2 parcial y actividad inhibidora de serotonina y/o noradrenalina.

Info

Publication number
MXPA04004745A
MXPA04004745A MXPA04004745A MXPA04004745A MXPA04004745A MX PA04004745 A MXPA04004745 A MX PA04004745A MX PA04004745 A MXPA04004745 A MX PA04004745A MX PA04004745 A MXPA04004745 A MX PA04004745A MX PA04004745 A MXPA04004745 A MX PA04004745A
Authority
MX
Mexico
Prior art keywords
dopamine
serotonin
partial dopamine
systems
partial
Prior art date
Application number
MXPA04004745A
Other languages
English (en)
Inventor
Roelof W Feenstra
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of MXPA04004745A publication Critical patent/MXPA04004745A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invencion se refiere al uso de un compuesto o una combinacion de compuestos que tienen actividad agonistica de receptor de dopamina-D2 parcial y actividad inhibidora de reabsorcion de serotinina y/o noradrenalina, para la preparacion de una composicion farmaceutica para el tratamiento de trastornos psiquiatricos y/o neurologicos causados por perturbaciones de los sistemas monoaminergicos principales (dopamina, serotonina y/o noradrenalina) o que pueden ser tratados mediante la manipulacion de esos sistemas.
MXPA04004745A 2002-02-14 2003-02-11 Agonista de receptor de dopamina-d2 parcial y actividad inhibidora de serotonina y/o noradrenalina. MXPA04004745A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20020076344 EP1336406A1 (en) 2002-02-14 2002-02-14 Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity
PCT/EP2003/050015 WO2003068207A2 (en) 2002-02-14 2003-02-11 Partial dopamine-d2 receptor agonist plus serotonin and/oder noradrenaline inhibitor activity

Publications (1)

Publication Number Publication Date
MXPA04004745A true MXPA04004745A (es) 2004-08-02

Family

ID=27619173

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04004745A MXPA04004745A (es) 2002-02-14 2003-02-11 Agonista de receptor de dopamina-d2 parcial y actividad inhibidora de serotonina y/o noradrenalina.

Country Status (16)

Country Link
US (1) US20050038015A1 (es)
EP (2) EP1336406A1 (es)
JP (1) JP2005517036A (es)
KR (1) KR20040081779A (es)
CN (1) CN1592614A (es)
AU (1) AU2003208714A1 (es)
BR (1) BR0306147A (es)
CA (1) CA2462688A1 (es)
HR (1) HRP20040276A2 (es)
IL (1) IL160942A0 (es)
MX (1) MXPA04004745A (es)
NO (1) NO20043833L (es)
PL (1) PL370632A1 (es)
RU (1) RU2004112546A (es)
WO (1) WO2003068207A2 (es)
ZA (1) ZA200404740B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL201178B1 (pl) 1999-08-23 2009-03-31 Solvay Pharm Bv Nowe pochodne fenylopiperazyny, sposób ich wytwarzania, kompozycja farmaceutyczna oraz zastosowanie
AR032712A1 (es) 2001-02-21 2003-11-19 Solvay Pharm Bv Un mesilato de derivados de fenilpiperazina y composiciones farmaceuticas que lo contienen
AR032711A1 (es) 2001-02-21 2003-11-19 Solvay Pharm Bv Derivados de fenilpiperazina, un metodo para la preparacion de los mismos y una composicion farmaceutica que los contiene
CA2453837C (en) * 2001-07-20 2011-10-04 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder using eltoprazine and related compounds
ATE376419T1 (de) 2002-12-27 2007-11-15 Otsuka Pharma Co Ltd Carbostyril-derivate mit selektiven serotonin- aufnahme inhibitoren, zur behandlung von gemütskrankheiten
AR042806A1 (es) * 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
GB0327195D0 (en) * 2003-11-21 2003-12-24 Smithkline Beecham Corp Novel use
EP1595542A1 (en) * 2004-03-26 2005-11-16 Solvay Pharmaceuticals B.V. Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds
US7596407B2 (en) 2004-03-26 2009-09-29 Solvay Pharmaceuticals, B.V. Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds
WO2007019880A1 (en) * 2005-08-18 2007-02-22 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of a selective inhibitor of norepinephrine reuptake for treating respiratory disorders resulting from rett syndrome
WO2007065713A2 (en) * 2005-12-08 2007-06-14 Axxonis Pharma Gmbh Use of 8-alpha-ergolines for the treatment of traumatic brain disorders
AU2008279572A1 (en) * 2007-02-01 2009-01-29 David Chau Combinations of dopamine D2 receptor blockade with norepinephrine reuptake inhibition and with norepinephrine alpha 2 receptor blockade
MX2010000937A (es) * 2007-07-23 2010-06-25 Synosia Therapeutics Inc Tratamiento del trastorno por estrés postraumático.
TW200936130A (en) * 2008-02-26 2009-09-01 Lundbeck & Co As H Uses of indane compounds
WO2011082266A2 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted heterocyclic compounds
ES2638309T3 (es) * 2010-04-19 2017-10-19 Nlife Therapeutics S.L. Composiciones y métodos para la distribución selectiva de moléculas de oligonucleótidos a tipos específicos de neuronas
CN111134894B (zh) * 2020-01-17 2022-02-22 上海长海医院 一种在体测定犬前列腺组织连续动态游离药物浓度的采样方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71590C2 (en) * 1998-11-13 2004-12-15 Duphar Int Res Piperazine and piperidine derivatives
PL201178B1 (pl) * 1999-08-23 2009-03-31 Solvay Pharm Bv Nowe pochodne fenylopiperazyny, sposób ich wytwarzania, kompozycja farmaceutyczna oraz zastosowanie

Also Published As

Publication number Publication date
HRP20040276A2 (en) 2005-04-30
EP1336406A1 (en) 2003-08-20
KR20040081779A (ko) 2004-09-22
US20050038015A1 (en) 2005-02-17
PL370632A1 (en) 2005-05-30
WO2003068207A2 (en) 2003-08-21
EP1476148A2 (en) 2004-11-17
CN1592614A (zh) 2005-03-09
AU2003208714A1 (en) 2003-09-04
ZA200404740B (en) 2005-08-23
JP2005517036A (ja) 2005-06-09
NO20043833L (no) 2004-09-13
CA2462688A1 (en) 2003-08-21
RU2004112546A (ru) 2005-03-27
WO2003068207A3 (en) 2003-12-18
BR0306147A (pt) 2004-10-19
IL160942A0 (en) 2004-08-31

Similar Documents

Publication Publication Date Title
MXPA04004745A (es) Agonista de receptor de dopamina-d2 parcial y actividad inhibidora de serotonina y/o noradrenalina.
TW200630096A (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
HK1094421A1 (en) (S)-2-n-propylamino-5-hydroxytetralin as a d3-agonist
TW200407305A (en) Novel compounds
MY133238A (en) Monoamine reuptake inhibitors for treatment for cns disorders
GEP20074197B (en) 5ht2c receptor modulators
WO2005103041A3 (en) Treatment of cns disorders using cns target modulators
TW200510301A (en) Novel compounds
TW200510303A (en) Novel compounds
RS20050392A (en) Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MX2009006339A (es) Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide.
TW200732296A (en) Novel compounds
TW200745031A (en) Acyl indoles, compositions containing such compounds and methods of use
MXPA03010232A (es) Compuestos de arilsulfonamida, para el tratamiento de la obesidad, de la diabetes tipo ii y de trastornos del sistema nervioso central.
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
TW200503710A (en) Novel compounds
MXPA04010625A (es) Antagonista de receptor de taquicinina.
MXPA05003640A (es) Compuestos de dihidropiridina que tienen capacidad simultanea para bloquear los canales de calcio del tipo l y para inhibir la actividad de la fosfodiesterasa del tipo 3.
WO2006023757A3 (en) Novel tricyclic, bicyclic, monocyclic, and acyclic amines as potent sodium channel blocking agents
WO2004052858A3 (en) Inhibitors of monoamine uptake
HRP20050336B1 (hr) Supstituirani tetralini i indani i njihova primjena
MXPA06000700A (es) Compuestos de sulfonildihidroimidazopiridinona como ligandos de 5-hidroxitriptamina-6.
RS20050318A (en) Substituted tetralins and indanes
GB0027020D0 (en) Treatment of movement disorders